Item 1.01. Entry into a Material Definitive Agreement.
Qualigen Therapeutics, Inc. (the "Company") and an institutional investor entered into a Securities Purchase Agreement dated July 5, 2024 (the "Agreement"), providing for the Company to issue to the investor at par a Senior Note with the following characteristics and terms, against the investor's loan of $2,000,000 in cash: (a) an original principal amount of $2,000,000, (b) unsecured, (c) nonconvertible, (d) scheduled maturity date of July 8, 2025, (e) interest at the rate of 18% per annum, (f) requirement for partial prepayments from a percentage of any future Company financings, and (g) otherwise, principal and interest on the Senior Note not payable until maturity.
The Agreement also required the Company Board of Directors resignations and appointments as set forth in Item 5.02 below.
The foregoing descriptions of the Agreement and the Senior Note do not purport to be complete and are qualified in their entirety by reference to the full text as set forth in Exhibit 10.1, which is incorporated herein by reference.
Attachments
Disclaimer
Qualigen Therapeutics Inc. published this content on 11 July 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 July 2024 21:26:23 UTC.